Irisin and therapeutics for duchenne muscular dystrophy

Ended Project Grant Awarded Last action

Award ID
W81XWH2110611
Recipient
Awarding agency
Obligated
$597,916

Award facts

Assistance listing
12.420 Military Medical Research and Development
Completion date
Place of performance
Boston, MA 02115, USA

Award details come from USAspending.gov.

About this award

Written by GovTribe AI ·

The Department of the Army Medical Command awarded a $597,916 project grant to Dana-Farber Cancer Institute, Inc. to support research on IRISIN AND THERAPEUTICS FOR DUCHENNE MUSCULAR DYSTROPHY. The grant was awarded on September 30, 2021 with a completion date of September 29, 2023. The funding supports the Military Medical Research and Development program, with the CFDA number 12.420, which aims to transform health care for service members and the public through innovative biomedical research investigating medical solutions for battlefield wounds. Specifically, the grant will fund Dana-Farber's research exploring the potential of IRISIN, a myokine, as a therapeutic for Duchenne muscular dystrophy.

Quick answers

Who received award W81XWH2110611?

W81XWH2110611 was awarded to Dana-Farber Cancer Institute, Inc. by Medical Command (Department of the Army) on September 30, 2021.

How much is award W81XWH2110611 worth?

$597,916 has been obligated on W81XWH2110611.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login